CRISPR Therapeutics stock jumps on early gene editing data
November 19, 2019 at 10:46 AM EST
CRISPR Therapeutics and Vertex Pharmaceuticals released the first data from their early-stage trial testing the safety and effectiveness of a potential cure for the genetic blood disorders sickle cell disease and beta thalassemia.